YKL-40 tissue expression and plasma levels in patients with ovarian cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Høgdall, Estrid V S ^a,b   Ringsholt, Merete ^c   Høgdall, Claus K ^b   Jarle, Ib Jarle ^b   Johansen, Julia S ^b   Kjaer, Susanne K ^a,b   Blaakaer, Jan ^d   Ostenfeld Møller, Lene ^b   Price, Paul A ^e   Christensen, Lise H ^b  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Faculty of Medical Laboratory Science   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CHITINASE; PROTEIN YKL 40; UNCLASSIFIED DRUG; CHI3L1 PROTEIN, HUMAN; GLYCOPROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAST CELL; NEUTROPHIL; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; BLOOD; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; OVARY TUMOR; RETROSPECTIVE STUDY;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 61849164601     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-8     Document Type: Article

References (30)

1. Bussink AP Speijer D Aerts JMFG Boot RG Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases Genetics 2007, 177:959-70 2034658 17720922 10.1534/genetics.107.075846
2. Johansen JS Jensen BV Roslind A Nielsen D Price PA Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006, 15:194-202 10.1158/1055-9965.EPI-05-0011 16492905
3. Coskun U Yamac D Gulbahar O Sancak B Karaman N Ozkan S Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: Are the changes in serum levels of YKL-40, MMP-2 and MMP-3 correlated with tumor response? Neoplasma 2007, 54:348-52 17845129
4. Kucur M Isman FK Balci C Onal B Hacibekiroglu M Ozkan F Ozkan A Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia Urol Oncol 2008, 26:47-52 18190830
5. Mylin AK Abildgaard N Johansen JS Andersen NF Heickendorff L Standal T Gimsing P Knudsen LM High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients Eur J Haematol 2008, 80:310-7 10.1111/j.1600-0609.2007.01027.x 18182077
6. Yamac D Ozturk B Coskun U Tekin E Sancak B Yildiz R Atalay C Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer Adv Ther 2008, 25:801-9 10.1007/s12325-008-0082-2 18670741
7. Biggar RJ Johansen JS Smedby KE Rostgaard K Chang ET Adami HO Glimelius B Molin D Hamilton-Dutoit S Melbye M Hjalgrim H Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma Clin Cancer Res 2008, 14:6974-8 10.1158/1078-0432.CCR-08-1026 18980992
8. Mitsuhashi A Matsui H Usui H Nagai Y Tate S Unno Y Hirashiki K Seki K Shozu M Serum YKL-40 as a marker for cervical adenocarcinoma Ann Oncol 2008 Aug. 22 18723551
9. Johansen JS Høyer PE Larsen LA Price PA Møllgård K YKL-40 protein expression in the early developing human musculoskeletal system J Histochem Cytochem 2007, 55:1213-8 10.1369/jhc.7A7245.2007 17712177
10. Ringsholt M Høgdall EVS Johansen JS Price PA Christensen LH YKL-40 protein expression in normal adult human tissues - an immunohistochemical study J Mol Histol 2007, 38:33-43 10.1007/ s10735-006-9075-0 17242979
11. Nutt CL Betensky RA Brower MA Batchelor TT Louis DN Stemmer-Rachaminov AO YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas Clin Cancer Res 2005, 11:2258-64 10.1158/ 1078-0432.CCR-04-1601 15788675
12. Pelloski CE Mahajan A Maor M Chang EL Woo S Gilbert M Colman H Yang H Ledoux A Blair H Passe S Jenkins RB Aldape KD YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma Clin Cancer Res 2005, 11:3326-34 10.1158/ 1078-0432.CCR-04-1765 15867231
13. Pelloski CE Lin E Zhang L Yung WK Colman H Liu JL Woo SY Heimberger AB Suki D Prados M Chang S Barker FG 3rd Fuller GN Aldape KD Prognostic associations of activated mitogen-activated protein kinase and akt pathways in glioblastoma Clin Cancer Res 2006, 12:3935-41 10.1158/ 1078-0432.CCR-05-2202 16818690
14. Phillips HS Kharbanda S Chen R Forrest WF Soriano RH Wu TD Misra A Nigro JM Colman H Soroceanu L Williams PM Modrusan Z Feuerstein BG Aldape K Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 2006, 9:157-73 10.1016/j.ccr.2006.02.019 16530701
15. Hormigo A Gu B Karimi S Riedel E Panageas KS Edgar MA Tanwar MK Rao JS Fleisher M DeAngelis LM Holland EC YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas Clin Cancer Res 2006, 12:5698-5704 10.1158/1078-0432.CCR-06-0181 17020973
16. Kim SH Das K Noreen S Coffman F Hameed M Prognostic implication of immunohistochemically detected YKL-40 expression in breast cancer World J Surg Oncol 2007, 5:17 1802867 17286869 10.1186/1477-7819-5-17
17. Roslind A Johansen JS Junker N Nielsen DL Dzaferi H Price PA Balslev E YKL-40 expression in benign and malignant lesions of the breast: A methodologic study Appl Immunohistochem Mol Morphol 2007, 15:371-81 18091378
18. Roslind A Knoop AS Jensen MB Johansen JS Nielsen DL Price PA Balslev E YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer Breast Cancer Res Treat 2008, 112:275-85 10.1007/ s10549-007-9870-7 18157633
19. Lau SH Sham JST Xie D Tzang CH Tang D Ma N Hu L Wang Y Wen JM Xiao G Zhang WM Lau GK Yang M Guan XY Clusterin plays an important role in hepatocellular carcinoma metastasis Oncogene 2006, 25:1242-50 10.1038/ sj.onc.1209141 16247463
20. Roslind A Johansen JS Christensen IJ Kiss K Balslev E Nielsen DL Bentzen J Price PA Andersen E High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival Int J Cancer 2008, 122:857-63 10.1002/ijc.23152 17957792
21. Junker N Johansen JS Andersen CB Kristjansen PE Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer Lung Cancer 2005, 48:223-31 10.1016/j.lungcan.2004.11.011 15829322
22. Volck B Price PA Johansen JS Sørensen O Benfield TL Nielsen HJ Calafat J Borregaard N YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils Proc Assoc Am Physicians 1998, 110:351-60 9686683
23. Høgdall EV Johansen JS Kjær SK Price PA Christensen L Blaakaer J Bock JE Glud E Høgdall CK High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival Oncol Rep 2003, 10:1535-8 12883737
24. Dupont J Tanwar MK Thaler HT Fleisher M Kauff N Henley ML Sabbatini P Anderson S Aghajanian C Holland EC Spriggs DR Early detection and prognosis of ovarian cancer using serum YKL-40 J Clin Oncol 2004, 22:3330-9 10.1200/JCO.2004.09.112 15310777
25. Dehn H Høgdall EVS Johansen JS Jørgensen M Price PA Engelholm SA Høgdall CK Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer Acta Obstet Gynecol Scand 2003, 82:287-93 10.1034/j.1600-0412.2003.00010.x 12694127
26. Grønlund B Høgdall EV Christensen IJ Johansen JS Nørgaard-Pedersen B Engelholm SA Høgdall C Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: Value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA125) Int J Biol Markers 2006, 21:141-48 17013795
27. Glud E Kjaer SK Thomsen BL Høgdall C Christensen L Høgdall E Bock JE Blaakaer J Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer Arch Intern Med 2004, 164:2253-9 10.1001/ archinte.164.20.2253 15534163
28. Høgdall EV Johansen JS Kjaer SK Price PA Blaakaer J Høgdall CK Stability of YKL-40 concentration in blood samples Scand J Clin Lab Invest 2001, 60:247-51 10.1080/00365510050184886
29. Pelloski CE Ballman KV Furth AF Zhang L Lin E Sulman EP Bhat K McDonald JM Yung WK Colman H Woo SY Heimberger AB Suki D Prados MD Chang SM Barker FG 2nd Buckner JC James CD Aldape K Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J Clin Oncol 2007, 25:2288-94 10.1200/JCO.2006.08.0705 17538175
30. Rousseau A Nutt CL Betensky RA Iafrate AJ Han M Ligon KL Rowitch DH Louis DN Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: Use of YKL-40, ApoE, ASCL1, and NKX2-2 J Neuropathol Exp Neurol 2006, 65:1149-56 10.1097/01.jnen.0000248543.90304.2b 17146289